|
Authors
|
Leonard, N. A.; Corry, S. M.; Reidy, E.; Egan, H.; O'Malley, G.; Thompson, K.; McDermott, E.; O'Neill, A.; Zakaria, N.; Egan, L. J.; Ritter, T.; Lössner, D.; Redmond, K.; Sheehan, M.; Canney, A.; Hogan, A. M.; Hynes, S.; Treacy, O.; Dunne, P.; Ryan, A. E.
|
|
Title
|
Tumour-associated mesenchymal stromal cells modulate macrophage phagocytosis in stromal-rich colorectal cancer via PD-1 signalling
|
|
Date
|
20.09.2024
|
|
Number
|
0
|
|
Abstract
|
CMS4 colorectal cancer (CRC), based on the consensus molecular subtype (CMS), stratifies patients with the poorest disease-free survival rates. It is characterized by a strong mesenchymal stromal cell (MSC) signature, wound healing-like inflammation and therapy resistance. We utilized 2D and 3D in vitro, in vivo, and ex vivo models to assess the impact of inflammation and stromal cells on immunosuppression in CMS4 CRC. RNA sequencing data from untreated stage II/III CRC patients showed enriched TNF-α signatures in CMS1 and CMS4 tumors. Secretome from TNF-α treated cancer cells induced an immunomodulatory and chemotactic phenotype in MSC and cancer-associated fibroblasts (CAFs). Macrophages in CRC tumours migrate and preferentially localise in stromal compartment. Inflammatory CRC secretome enhances expression of PD-L1 and CD47 on both human and murine stromal cells. We demonstrate that TNF-α-induced inflammation in CRC suppresses macrophage phagocytosis via stromal cells. We show that stromal cell-mediated suppression of macrophage phagocytosis is mediated in part through PD-1 signaling. These data suggest that re-stratification of CRC by CMS may reveal patient subsets with microsatellite stable tumors, particularly CMS4-like tumors, that may respond to immunotherapies.
|
|
Publisher
|
Elsevier
|
|
Wikidata
|
|
|
Citation
|
iScience 27 (2024) 110701
|
|
DOI
|
https://doi.org/10.1016/j.isci.2024.110701
|
|
Tags
|
|
